PD-1/PD-L1抑制剂治疗NSCLC脑转移的免疫机制与临床研究进展
Zhongguo fei ai za zhi = Chinese journal of lung cancer（2020）
Abstract
脑转移是非小细胞肺癌(non-small cell lung cancer,NSCLC)的常见并发症,预后较差.近年来,免疫检查点抑制剂将恶性肿瘤的治疗带入新纪元.程序性死亡因子-1(programmed death-1,PD-1)/程序性死亡因子配体-1(programmed death ligand 1,PD-L1)抑制剂通过激活自身免疫系统,产生抗肿瘤效应.PD-1/PD-L1抑制剂在NSCLC脑转移治疗中初露锋芒,但其确切疗效及最佳治疗模式仍有待进一步研究.本文针对NSCLC脑转移灶的免疫微环境,PD-1/PD-L1抑制剂在颅内的作用机制及其临床研究现状进行综述.
MoreTranslated text
Key words
Brain metastasis,Immunotherapy,Lung neoplasms,PD-1/PD-L1
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined